SOUTH SAN FRANCISCO, Calif., Feb 15, 2011 (BUSINESS WIRE) -- Exelixis, Inc. (NASDAQ:EXEL) will hold an investor briefing webcast in conjunction with the American Society of Clinical Oncology 2011 Genitourinary Cancers Symposium (ASCO GU). The webcast will be held this Thursday, February 17, 2011, from 6:30-8:00 p.m. EST. The webcast may be accessed by visiting the Event Calendar page under Investors at www.exelixis.com.

During the briefing, Exelixis management will review the latest clinical data for cabozantinib (XL184) in castration-resistant prostate cancer (CRPC), which will be presented at the ASCO GU meeting on Thursday afternoon (full logistical details below). Management will also discuss the pivotal trial plans and regulatory strategy for CRPC, as well as opportunities for cabozantinib outside of CRPC.

In addition to Exelixis management, participants in the briefing will include:

• Philip Kantoff, M.D., Chief, Division of Solid Tumor Oncology, Chief Clinical Research Officer and Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
• Howard Scher, M.D., Chief of Genitourinary Oncology Service at the Sidney Kimmel Center for Urologic and Prostate Cancers at Memorial Sloan-Kettering Cancer Center
• Matthew Smith, M.D., Ph.D., Director of the Genitourinary Malignancies Program at the Massachusetts General Hospital Cancer Center

An archived replay will be available on the Event Calendar page under Investors at www.exelixis.com and via phone until 11:59 p.m. EST on March 17, 2011. Access numbers for the replay are: 1-888-286-8010 (domestic) and 1-617-801-6888 (international). The replay passcode is 59328118.

Cabozantinib (XL184) Data at the ASCO 2011 GU Symposium

Investigators will present updated data from the randomized discontinuation trial of cabozantinib in patients with CRPC at the meeting. The abstract, #127, will be available on the ASCO website (http://www.asco.org) starting at 6:00 p.m. EST today; however, these data pre-date publication of data at the EORTC-NCI-AACR Symposium in November 2010. The full ASCO GU poster -- "Phase 2 Study of Cabozantinib (XL184) in a Cohort of Patients with Castration-Resistant Prostate Cancer and Measurable Soft Tissue Disease" -- will include updated and additional details not present in the abstract. It will be presented on Thursday, February 17, 2011, from 4:50-6:20 p.m. EST in the meeting's General Poster Session B and will also be available on www.exelixis.com beginning at that time.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, and Daiichi-Sankyo. For more information, please visit the company's web site at www.exelixis.com.

SOURCE: Exelixis, Inc.

Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President, Investor Relations and Corporate Communications
cbutler@exelixis.com